Pembrolizumab in Metastatic Anal Cancer

• Status: Recruiting
• Trial end date: 2023-03-01

Summary

This research study is studying a targeted therapy as a possible treatment for advanced anal cancer.

The following intervention will be involved in this study:

-Pembrolizumab

• Phase: Phase 2

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Pembrolizumab